In addition, there is a study that uses alpelisib, a PIK3CA inhibitor, for breast cancer PIK3CA mutated patients, who have shown better survival than that of other treatment [49], which could be implemented in lung cancer as well. This evidence concerns the gene PIK3CA and breast cancer.